Last reviewed · How we verify

NCT00165724

Alzheimer's Disease Long-term Follow-up Study (ALF Study)

Completed Phase 4 Last updated 30 December 2021
What this trial tests

Phase 4 trial testing Donepezil Hydrochloride in Alzheimer's Disease in 114 participants. Completed in 31 December 2006.

Timeline
30 June 2004
Primary endpoint
31 July 2006
31 December 2006

Quick facts

Lead sponsorEisai Korea Inc.
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment114
Start date30 June 2004
Primary completion31 July 2006
Estimated completion31 December 2006
Sites7 locations across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Eisai Korea Inc. — full company profile →

Who can join

Adults 40 to 90, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open study for efficacy and safety of donepezil treatment during 48 weeks

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Donepezil Hydrochloride

Trials testing the same drug.

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

Other Eisai Korea Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00165724.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing